Roche
NEWS
Roche Wins Approval for Flu Drug in Young Children, Pfizer Touts Positive Results for Infant Vaccine
Roche and Pfizer shared positive news from their respective forays into a new pneumococcal vaccine for infants and a treatment for influenza in small children.
The real positive drivers were Eylea and Dupixent. Eylea climbed 14% to $1.62 billion, while Dupixent sales jumped almost 40% to $2.09 billion for the second quarter.
Roche signed a big $6 billion-plus collaboration deal with Poseida on blood cancers while its partner, AC Immune, parsed failed data on an Alzheimer’s drug to suggest a positive spin.
As the second financial quarter of the year comes to a close, pharma and biotech companies are releasing their financial results. For more information on the top-earning companies, read on.
As Severin Schwan prepares to step aside from the day-to-day leadership of Roche, Thomas Schinecker is waiting in the wings to assume the company’s top leadership spot.
Avista Therapeutics inked a partnership deal with Swiss pharma giant Roche to develop AAV gene therapy vectors for eye diseases.
Roche had a good week, sharing positive data from Genentech’s study on Vabysmo for age-related macular degeneration and its breast cancer combination therapy, Perjeta.
Early data from Amgen’s ongoing trial on Lumakras for non-small cell lung cancer hinted at positive results from what could be a transformative combination of drugs versus cancer.
uniQure gave a 12-month update on AMT-130, the first-ever AAV gene therapy for HD to enter clinical trials. BioSpace spoke with the company’s president of R&D, Dr. Ricardo Dolmetsch.
JOBS
IN THE PRESS